Erytech Pharma, MD Anderson Ink Companion Dx Deal

The French firm will work with MD Anderson on a potential companion diagnostic for its drug candidate for treating solid tumors.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories